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Nonarterialized orthotopic liver transplantation 
with no immunosuppression was performed in 13 
mouse-strain combinations. Two strain combinations 
with major histocompatibility complex class I and class 
II and minor histocompatibility complex disparity had 
20% and 33% survival of more than 100 days, but the 
other 11 combinations, including four that were fully 
allogeneic and all with only class I, class II or minor 
disparities, yielded 45% to 100% survival of more than 
100 days. Long-living recipients permanently accepted 
donor-strain heterotopic hearts transplanted on the 
same day or donor-strain skin 3 mo after liver trans-
plantation, in spite of detectable antidonor in vitro 
activity with mixed lymphocyte reaction and cell-
mediated lymphocytoto:s:icity testing (split tolerance). 
In further donor-specific experiments, liver grafts 
were not rejected by presensitized m.qor histocompat-
ibility complex clasa I-disparate recipients and they 
protected donor-strain skin grafts from second set (or 
any) rejection. Leu frequently, liver transplantation 
rescued rejecting skin grafts placed 1 wk earlier in 
m.qor histocompatibility complex class I, class II and 
minor histocompatibility complex, class II or minor 
histocompatibility complex-disparate strain combina-
tions. Donor·derived leukocyte migration to the 
central lymphoid organs occurred within 1 to 2 hr after 
liver transplantation in all animals examined, per-
sisted in the surviving animals until they were killed 
(> 375 days), and was demonstrated with double-immu-
nolabeling to be multilineage. The relation of these 
findings to so-called hepatic tolerogenicity and to 
tolerance in general is discussed. (HEPATOLOGY 1994;19: 
916-924.) 
We have proposed that a reciprocal migration of 
leukocytes of bone marrow origin between graft and 
host, with subsequent chimerism in both, is the first step 
toward donor-specific nonreactivity (tolerance) that may 
or may not require immunosuppression (1-7). According 
to this concept, the variable tolerogenicity and ease of 
"acceptance" of different organs merely reflect the 
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comparative content ofthese multilineage leukocytes, of 
which the antigen-presenting dendritic cell defined as a 
distinct lineage by Steinman and Cohn (8,9) is the most 
critical (1-7). In our study of liver transplantation in 
mice, we have examined the effect of major histocom-
patibility complex (MHC) on hepatic tolerogenicity and 
chimerism, with further attention to the lineages and 
traffic of the donor leukocytes. 
MATERIALS AND METHODS 
Animals and Procedurell 
Ten- to 12-wk-old male mice with varying H-2 histocompat-
ibility genotypes (Table 1) were purchased from the Jackson 
Laboratory (Bar Harbor, ME) and housed in a pathogen-free 
facility. All operations and procedures were carried out with 
mice under methoxyflurane (2.2-dichloro-1,l-difluoroethyl 
methyl ether) anesthesia. 
Liver TraJUlplGntation. The allograft was placed in the 
normal location after removal of the recipient's liver. It was 
revascularized with a combination of suture and cuff tech-
niques. The hepatic artery was not reconstructed.. This 
operation has been described. in detail elsewhere (10) and is 
fundamentally the same as developed. first in dogs (11) and 
human beings (12), and then used experimentally in pigs (13) 
and other large animals. In mice (10) and rats (14), hepatic 
arterialization is not necessary. Cholecystectomy was per-
formed., and bile duct patency was assured with a fine 
polyethylene tube stent. Immunosuppression was not used. 
Animals that died within 1 week after transplantation were 
classified. as technical failures (10% to 15% of total operations) 
and excluded from analysis. Tissues were usually harvested. 
after the animal had been killed, but in some cases wed.ge 
resection biopsies of the liver were performed at reoperation 
without the animals being killed. 
Hearl Tra""plGntation. The intraabdominal operation was 
adapted. from the rat procedure ofOno and Lindsey (15), with 
daily monitoring of the heart grafts by palpation through the 
abdominal wall. Rejection was defined. by the cessation of 
cardiac impulses and confirmed by exploration and histological 
examination. 
Skin TraJUlplantation. A full-thickness skin graft from the 
donor tail (8 mm x 8 mm) was placed on the recipient's dorsal 
side by the method of Billingham et aI. (16l. The graft was held 
in place by the dressing and a tape for 7 to 8 days and inspected 
daily thereafter. Rejection was defined as the day of complete 
graft destruction. 
Tisllue Collections 
With the few exceptions in which wed.ge biopsies were 
performed. the liver recipients were killed 1 hr to more than 
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TABLE 1. H·2 Haplotypes 
Strains H·2 haplotype 
C57BlIIO (BI0) b 
C3H k 
BI0.BR k 
BI0.AKM m 
A.TH t2 
A.TL tl 
A.SW s 
C57B1I6 b 
BI0.D2 d 
BI0.HTG g 
DBA2 d 
K 
b 
k 
k 
k 
s 
s 
s 
b 
d 
d 
d 
Alleles at H·2 loci 
A E 
b b 
k k 
k k 
k k 
S s 
k k 
s s 
b b 
d d 
d d 
d d 
D 
b 
k 
k 
q 
d 
d 
s 
b 
d 
b 
d 
TABLE 2. Primary monoclonal antibodies used for immunohistochemical studies 
Specificity Clone Isotype 
H·2Kb 
H·2Kk 
Y·Ek 
I·Ab 
AF6·88.5 
36·7·5 
14·4-43 
AF6·120.1 
Mouse IgG2ua 
Mouse IgG28 a 
Mouse IgG2a a 
Mouse IgG2u· 
Goat IgG' 
Rat IgG2bc 
Rat IgG2bc 
Rat IgG2bd 
Rat IgG2: 
IgM (IJ. chain) 
Thy 1.2 (T ceil) 3D·H12 
iC3bR (M0) 
F4/80 (M0IDCl 
(DC·associated antigen) 
(DC· associated antigen) 
CD45R (B celi) 
Ml/70 (TIB1281 
HB 198 
NLDC 145 
2Al 
B220 (TIB 145) 
Rat IgG2! 
Rat IgG2.a 
·PharMingen, San Diego, CA. 
bVector Laboratories, Burlingame, CA. 
cBoehringer Mannheim, Indianapolis, IN. 
dAmerican Type Culture CoUection, Rockville, MD. 
• Accurate Chemical and Scientific Corp., Westbury, NY. 
'Gift from Professor Ralph Steinman, RockefeUer University, New York, NY. 
375 days after surgery. Lymphoid and nonlymphoid organs 
were harvested and placed in the embedding medium (Tis· 
sue·Tek O.C.T. Compound; Miles Inc., Elkhart, IN), snap· 
frozen in liquid nitrogen and stored at - 80° C until sectioning. 
Cryosections were cut at 4 IJ.m, mounted on precleaned slides, 
dried overnight at room temperature, fixed in acetone for 5 min 
and subsequently rehydrated with PBS. 
ImmulWhistochemical Staining 
Donor cells were localized within the recipient tissues and 
the liver allografts with the use of a direct immunoperoxidase 
procedure. Endogenous biotin was blocked with the avidin· 
biotin blocking reagent (Vector Laboratories, Inc., Bur· 
lingame, CAl for 20 min each. The tissues were incubated with 
nonfat dried milk for 20 min and, after two washes with PBS, 
were reacted for 45 min with the biotinylated donor·specific 
class I or class II monoclonal antibodies or an isotype·matched 
biotinylated control (negative-staining control) and then 
washed in PBS (twice for 5 min). Endogenous peroxidase 
activity in the tissues was then quenched with 0.6% H20 2 for 
4 min and washed in PBS (twice for 5 min). The primary 
antibody was localized with streptavidin-conjugated per· 
oxidase for 30 min and washed in PBS (twice for 5 min), and 
the reaction was developed with 3-amino-5·ethycarbizol (9 
min). The slides were counterstained with Harris' hematoxylin 
and mounted with Gelvatol (Monsanto, St. Louis, MOl. 
A double immunofluorescence (DIF) procedure was used to 
identify the lineages of donor cells in recipient tissues and 
grafted livers. The procedure adopted to localize donor cells 
was identical to immunoperoxidase staining, except that 
endogenous peroxidase activity was not quenched, and biotin· 
ylated primary monoclonal antibody was visualized with 
streptavidin·conjugated Cy3 (Jackson Immunoresearch Labo· 
ratories, Inc., West Grove, PAl. 
After localization of the donor cells with the use of antidonor 
MHC class I or II antibodies (with the above DIF technique), 
IgM + cells were identified by use of FITC.conjugated goat 
anti mouse IgM (IJ. chain specific). T cells, B cells, macrophages 
and dendritic cell lineages were identified by use of an indirect 
IF technique with the rat monoclonal antibodies to mouse 
shown in Table 2. These primary immunoreactants were then 
visualized by using mouse-adsorbed, FITC·conjugated goat 
antirat IgG. Donor class I or II positive cells that were negative 
for the specific lineage marker being tested were stained pure 
red. Cells of the recipient origin and bearing the appropriate 
lineage marker stained green, whereas donor cells expressing 
the appropriate lineage stained yellow. Technical controls for 
each lineage marker included staining of normal BIO lymphoid 
tissue (positive control), substitution of isotype-matched irrel· 
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TABLE 3. Survival of liver allografts in different strains acrotlll variOU8 histocompatibility barriers 
Strain MBC Liver graft 
combinatiolUl disparity survival (dB,.) 
C3H-+B10 I, II, mHC 8,15,35,41, > 100 
B10 ...... C3H I, II, mHC 18,51, > 100, > 100, > 100, > 100, > 100, > 100, 
> 100, > 100, > 100, > 100 
BALB/C ...... C3H I, II, mHC 8,13,15,15,16,52, > 100, > 100, > 100 
C3H ...... C57B1I6 I, II, mHC 13,20,45, > 100, > 100, > 100, > 100 
B10.BR-B10.02 I, II 9,10,11,16,18,18, > 100, > 100. > 100, > 100,> 100 
B10.BR-BlO I, II 17, > 100, > 100, > 100, > 100 
A.TH .... ATL II 7,14,14,18,83, > 100, > 100, > 100, > 100,> 100 
ATL ...... A.TH II 55,56, > 100, > 100, > 100. > 100. > 100 
ASW .... A.TH I 16, > 100, > 100, > 100, > 100 
BlO.AKM-BI0.BR I 81, > 100, > 100, > 100, > 100, > 100 
BI0.02 .... B1OJHTG I 14, > 100, > 100, > 100, > 100 
B10.BR-C3H mHC 22, > 100, > 100. > 100, > 100 
OBA2 .... BlO.02 mHC > 100, > 100, > 100 
TABLE 4. Skin graft survival 3 mo after successful liver tr8D8plantation 
Liver donor Recipient Disparity 
None C3H 
None C3H 
B10 C3H I, II, mHC 
B10 C3H 
None B10.BR 
None B10.BR 
B10.AKM B10.BR 
BlO.AKM BlO.BR 
None ATL 
None ATL 
A.TH ATL II 
A.TH A.TL 
None C3H 
None C3H 
BlO.BR C3H mHC 
BlO.BR C3H 
UAnimal died of intestinal obstruction with living skin graft. 
TABLE 5. Liver transplantation 1 wk after skin grafting 
rescues some rejecting skin grafts 
Skin Skin 
graft grafts 
(dBYIII CombinatioM Dlllparity rescued 
-7 BlO-C3H I, II, mHC 1 of 4 
-7 A.TL-A.TH [l 1 of 3 
-7 BlO.BR-C3H mHC 2 of 3 
evant antibodies (negative contro\) and staining of the liver 
allograft ("cross-reactIOn" contro!). The presence of the three 
distinct colors \ meamng three types of cells) in lymphoid 
tissues, the complete absence of red or green staining in the 
negative controls and red-only staining of the bile ducts when 
the donor liver was reacted with both donor-specific mono-
clonal antibodies to MHC and leukocyte lineage markers were 
used to verify the results. Slides were viewed on a Nikon 
epiftuorescent microscope (Nikon Instrument Group, Melville, 
:--.IJ) equipped with a DAPIIFITClTexas Red triple band pass 
filter \ Fryer Co .• Huntley, ILL 
Skin donor Skin II1Il'Vival (dB,.) 
B10 13,13,15,18,19 
BlO.02 12.13,13,14 
B10 39, > 100, > 100, > 100 
B10.02 13,13,13 
B10.AKM 20,20,23,23,23 
B10.02 13,13,14,14 
B10.AKM 20, > 100, > 100, > 100, > 100, > 100 
B10.D2 13,13,13,13 
A.TH 14,16,19,19,19 
BALB/C 12,13,13,13 
A.TH 56,°> 100,> 100 
BALB/C 12,12,12 
BlO.BR 20,22,22,23 
BlO.02 13,13,13,13 
BlO.BR > 100,> 100 
BI0.D2 13,13,14 
In some of the immunolabeling studies. class I and II surface 
antigen expression was augmented by an intraperitoneal 
injection of 4 x 106 units of recombinant interferon·'Y (r-
interferon-'Y) (Schering·Plough, Kenilworth. NJ) 2 days before 
the animal was killed. Interferon-'Y pretreatment did not 
change the pattern of chimerism, but it facilitated the ease of 
recognition of donor cells in long-term allograft recipients. The 
technique has been reported elsewhere \ 17). 
In Vitro Immunologic Tests 
Unidirectional mixed lymphocyte reaction was measured in 
recipients from nonreJecting strain combinations that were 
killed 30 days after liver transplantation for immunohis-
tochemical studies. Irradiated (20 Gy) donor and third-party 
lymphocytes were used as stimulators and cells isolated from 
the recipients' spleens as responders. In addition. the cytolytic 
activity of the recipient's splenic lymphocytes toward donor 
and third-party targets was assessed in cell-mediated lym-
pholysis (CML) assays. Effector lymphocytes were incubated 
with [; lCr-labeled target cells at 100: 1 effector/target ratios. 
More complete studies over the whole range of survival are 
reported elsewhere (18). 
'" 
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TABLE 6. Liver graft protects the second donor skin graft in presensitized recipient in BIO.AKM ..... BIO.BR 
strain combination 
Day j -14 to -28) 
First skin 
First skin 
l'il'llt BIO.AKM skin 
8UJ'Vival jdays) 
18.19.20,20.20.22 
18.18.19.22.22 
"Skin was rejected but animal survived. 
Day 0 
Liver 
Day (31·68) 
Second skin 
Second skin 
Second BIO.AKM 
akin mrvival (days) 
13.13.13.13.13.13 
46.0 > 100. > 100, > 100. 
> 100. > 100. > 100. 
> 100. > 100 
TABLE 7. Survival of simultaneous heterotppic cardiac transplants of donor origin in recipients of liver allografts 
Strain combinations 
BlO--C3H 
A.TH--A.TL 
BlO.AKM-BlO.BR 
BlO.BR-C3H 
aOrthotopic liver transplantation. 
RESULTS 
MHe disparity 
I.II,mHC 
II 
I 
mHC 
Survival After Liver Transplantation. Fatal rejec-
tion was consistently seen only with CPe~Bll and 
BAiB/C~CPe (Table 3), but even in these groups 20% 
and 33%, respectively, of recipients (disparate at class I, 
class II and minor histocompatibility complex) had 
survival of more than 100 days. Fifty-five of 78 liver 
recipients in the other 11 groups whose donors had 
histocompatibility disparities ranging from fully allo-
geneic to minor survived more than 100 days. This 
outcome was accomplished more regularly when there 
was MHC class I and II or class II compatibility (Table 
3), the strain combinations of which essentially all 
animals had permanent survival. However, 70% or 
better survival was also recorded in several strain 
combinations with disparate MHC class II, class I or 
both. 
The results were influenced by the strain direction of 
the organ transfer. CPe~Bll transplantations fared 
badly (1 in 5 liver grafts accepted more than 100 days), 
whereas with Bll~CPe 10 of 12 had more than 100-day 
survival. A smaller directional influence was seen with 
the AKqe~AKqi class II combination (Table 3), 
Hepatic Tolerogenicity 
Mter we determined the most predictably nonre-
jecting strain combinations by the foregoing studies, 
four pairings covering the spectrum of histoincompat-
ibility were selected for studies of hepatic tolerogenicity 
for other grafts. 
Skin Transplantation. Three months after suc-
cessful liver transplantation, donor-strain skin grafts 
were accepted no matter what the MHC disparity, with 
only two exceptions in a total of 15 mice (Table 4), The 
delayed skin transplantations did not adversely affect 
the preexisting liver allografts. All third-party skin 
grafts were rejected at the expected times. 
No OL1" 
7.7,7,7,7,10,10 
9,11,19,22,23 
Heart 8UJ'Vival (days) 
With OLT 
> 100, > 100 
> 100, > 100 
9.25, > 100, > 100. > 100 
13,13,13,13.14 > 100. > 100. > 100 
In 10 additional experiments with total, class II and 
minor incompatibilities, liver transplantation from 
the same donor strain was performed 7 days after 
rather than before skin transplantation. Four of the 
10 skin grafts were rescued from their expected fate 
of rejection (which normally occurred at about 2 to 
3 wk), but this outcome was accomplished more than 
once only with the BfMKBo~CPe strain combination, 
which is minor histocompatibility complex incom-
patible (Table 5). 
In further sensitization experiments with the class 
I-disparate BllKAhM~BllKBo strains, accelerated re-
jection was produced by repeat skin grafts (Table 6). The 
second-set rejections were prevented in nine of nine 
experiments by an intervening BlO.AKM liver trans-
plantation, which erased the memory of the previous 
exposure; eight of the nine skin grafts survived perma-
nently (Table 6). 
Heart Transplantation. Strong hepatic toleroge-
nicity was observed when donor-strain heart was trans-
planted on the same day as liver replacement. Instead of 
being rejected after 7 to 23 days (variable with different 
MHC disparities), all of the hearts protected by concomi-
tantly transplanted livers survived permanently 
(Table 7). 
Similar experiments were planned with the class I 
disparity of BfMKAhM~BllKBoK However, the control 
cardiac grafts were permanently accepted by three of the 
five normal BlO.BR mice (Table 7). This self-induction 
of tolerance by the heart made hepatic tolerogenicity 
studies impossible. 
Histopathologic Evidence of Chimerism 
Systemic chimerism was looked for in the organs of 
liver recipients 7 mo after transplantation in fully 
disparate Bll~CPe (class I, II, minor disparate) com-
binations. 
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FIG. L Recipient spleen 7 mo after liver transplantation in the 
BIO-->C3H combination stained for donor-specific MHC class II [l _Ah] 
antigens. The majority of donor cells were found in the periarterial 
lymphatic sheath and the marginal zone (immunoperoxidase staining 
for I-Ab, counterstained with hematoxylin ; original magnification 
x 40). Inset: (original magnification x 400 ) shows the individual cell 
staining (arrow) in greater detail. 
Sparse donor-specific class 1- or class II-positive cells 
could always be found. They were most easily detectable 
in the recipient's lymphoid organs (spleen, mesenteric 
lymph nodes and thymus) (Figs. 1, 2 and 3) . Donor cells 
were also identified in small numbers in the recipients' 
peripheral lymph nodes, small bowel, skin, kidney, 
tongue, heart and lung. 
The migrant donor cells found in recipient tissues 
long after transplantation were detected by double 
immunolabeling using antidonor MHC class I or II 
mAb and lineage-restricted leukocyte markers. The 
phenotype of donor cells identified included B cells 
(B220 and IgM positive), T cells (Thy 1.2 positive), 
macrophages (Ml170 and F4/80 positive) and dendritic 
cells (NLDC-145 and 2A1 positive). B cells were the 
most frequently detectable chimeric cells (about 60% 
of total), followed by T cells, dendritic cells and mac-
rophages. These cells were the same lineages as dem-
onstrated with flow cytometric analysis of nonparen-
chymal cells isolated from normal mouse liver (18). The 
multilineage nature of the chimerism was evident at 
all time points tested. 
The chimeric B cells (Fig. 3A) were detected mainly in 
the B-cell follicles of the recipient spleen. Analogous 
homing of donor B cells to normal sites of trafficking was 
also noted in lymph nodes. Donor dendritic cells and T 
cells were most frequently located in the splenic periar-
terial lymphatic sheath, mingled with recipient T cells 
and dendritic cells (Fig. 3B and C). 
In Vitro Immunologic Reactivity 
Splenocytes of C3H recipients of B10 livers showed 
alloreactivity toward the irradiated spleen cells of both 
the donor (B10) and third-party (BALB/C) animals. The 
alloreactivity was similar to that oflymphocytes isolated 
from naive C3H animals (Table 8). The cell-mediated 
lymphotoxicity (CMU activity (CMU of the stimulated 
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splenocytes from the liver-transplanted mice 30 days 
after transplantation was essentially the same against 
donor and third-party targets, whereas the killing of 
syngeneic targets was less than 10% (Table 9). The 
antidonor immunologic reactivity was maintained 
throughout the observation period from wk 1 through 
wk 12 in our study. 
DISCUSSION 
An unanticipated advantage of the mouse liver trans-
plantation model was that permanent graft acceptance 
could be achieved in all strain combinations without 
immunosuppression and reliably so with most. Failure 
of success to correlate with class I MHC compatibility 
was non supportive of an earlier hypothesis that se-
cretion by the liver of new soluble class I antigens is the 
basis of its tolerogenicity (19). The acceptance self-
induced by the liver extended, to other donor-strain 
tissues and organs, and could be used to rescue them 
from a second-set rejection caused by previous sensiti-
zation or less frequently from ongoing rejection _ Thus, 
the full spectrum of "hepatic tolerogenicity" (5, 6, 20) 
was exhibited in the absence of immunosuppression . 
Liver transplantation without treatment is also possible 
in a few rat-strain combinations (14, 21, 22) but not in 
outbred large animals (including human beings) with 
the exception of pigs (13, 20, 23 , 24). 
The ability to induce tolerance is not unique to the 
liver, only much stronger than that possessed by other 
organs (1-6) . Russell et al . (25 ) showed that mice that 
permanently accepted weakly histoincompatible kidneys 
without treatment were subsequently tolerant of skin 
from the donor strain. Corry et al. (26) described a 
mouse-strain combination that was nonrejecting for 
hearts, similar to one of our heart experiments in which 
there was an MHC class I disparity EBflKAhls1~ 
B10.BR). Though chimerism was not looked for in these 
earlier experiments, it is now the presumed explanation 
for the unexpected historical results. 
The association of hematolymphopoietic chimerism 
with acquired tolerance (15, 27 ) and graft vs . host 
disease (28) was discovered by Billingham et al . (27). The 
cause-and-effect relation was formally verified by 
Russell (29), who reversed both tolerance and runt 
disease (graft-vs.-host disease) in the Billingham et al . 
(27) model by the simple expedient of eliminating the 
chimerism with antidonor leukocyte antibodies . How-
ever, because chimerism was not realized to be a feature 
of successful whole-organ transplantation, it has been 
widely assumed that the" acceptance" of organ grafts is 
by different mechanisms than successfully engrafted 
bone marrow. Revision of this entrenched miscon-
ception has been mandated by the recent demonstration 
with sensitive cytostaining and polymerase chain re-
action techniques that microchimerism is invariably 
present after successful whole-organ transplantation in 
human beings (1-6) and rats (7). 
In fact, the microchimerism observed in our mouse 
liver transplant experiments (reported here) was strik-
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FIG. 2. Double immunofluorescent staining (DIF) controls for lineage identity of donor cells in recipient tissues. (a) No staining was seen in 
negative controls (see "Materials and Methods" ; original magnification x 400). (b) DIF staining of normal BID lymph node (positive controll 
with anti-I-Ab (red, non-B cells) and anti-B-220 (green, B cells). Note red cells in the paracortex, which are only positive for I-Ab; the green cells 
in the cortex, which are only positive for B-220; and the yellow cells (class II-positive B cells), which are double positive for both I-Ab and B-220 
(original magnification x 200). (c) DIF staining of the allografted liver with anti-I-Ab (red) and anti-B-220 (green) served as an additional control 
(original magnification x 400) Note red-only staining of biliary epithelium (donor I_Ab) and green-only staining of infiltrating recipients 
B-220-positive B cells . Lack of double-staining in bile ducts excludes possibility of nonspecific cross-reactivity of immunohistochemical reagents 
used. Arrow highlights lipofuscin autofluorescence. 
TABLE 8. Mixed lymphocyte response of spleen cells isolated from liver graft recipients (B1O ...... C3H) 30 days 
after transplantation 
Responders 
C3H (n = 3) 
C3H ( > OLT) (n = 3) 
aData expressed as mean cpm :!: 1 S.D. 
C3H 
6,720 :!: 653 
9,169 ::: 732 
ingly similar to that reported many years ago by Liegeois 
et al. (30, 31) in mouse bone marrow experiments that 
were designed to explain why animals treated by Monaco 
and colleagues (32, 33) with antilymphocyte serum plus 
delayed (1 wk later) intravenous bone marrow had 
developed donor-specific nonreactivity to skin grafts. 
With karyotyping, Liegeois et al. (30, 31) demonstrated 
progressively declining numbers of replicating donor 
bone marrow cells in the recipients' spleens for as long 
as 134 days, a condition for which they proposed the 
term "microchimerism." The assumption by Liegeois et 
al. (30, 31) and others (34) that the decline in donor cells 
Stimulators 3R TdR incorporation" 
BI0 
28,921 :!: 1,341 
27,540 0:: 2,731 
BALBIC 
22,868 ::: 1,562 
22,595 :!: 987 
signaled the impending disappearance of these leuko-
cytes obscured the importance of the early work. 
In addition, it was not remotely suspected, until our 
recent clinical (1-6) and experimental (7) studies, that 
the finding of microchimerism after bone marrow 
infusion is mimicked by migratory donor leukocytes 
from whole organs. For the low-level chimerism (usually 
< 0.1 %) to have a potent and sustained tolerogenic 
effect, an amplification process is required. Our hy-
pothesis (5, 7, 35) is that the donor leukocytes of bone 
marrow origin that are contained in all whole organs 
represent a functional fragment of the donor immune 
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FIG . 3. Lineage identification of donor cells by double immunofluorescent staining (DIF) in recipients' spleen 7 mo after OLT in BIO-->C3H 
combination. (a) DIF staining for donor I-Ab (red) and B-220 (B cells, green; original magnification x 100). A splenic arterial branch is located 
in the center. Single-positive donor non-B cells (large arrowhead, red-only) and double-positive donor B cells (small arrowhead, yellow) are 
located in the PALS . Inset: Yellow double-positive donor-B cell in greater detail (original magnification x 400) . (b) Donor leukocytes of dendritic 
cell lineage could also be detected by DIF labeling (original magnification x 400 ). Red-only donor cell in the PALS is positive for donor I-Ab (large 
arrowhead), whereas green-only cells stain positive with mAb 2Al (dendritic cell marker). The double-positive {bright yellow} cell is a donor 
dendritic cell (small arrowhead), which is stained for both donor class II and dendritic cell-associated antigen 2A1. (c) Donor T cells were also 
detected with DIF staining (original magnification x 400). Note red cells (large arrowhead), which are positive for donor MHC class I antigens 
(H-2Kb) alone; green cells, which are positive with mAb Thy 1.2 (T cells) alone; and donor T cell {bright yellow}, which is positive for both donor 
class I and Thy 1.2 (small arrowhead). The Thy 1.2-stained cell could be a fibroblast , but confirmatory evidence of a donor subpopulation of 
T cells was obtained by double labeling with donor class I and CD4 or CD8. 
TABLE 9. Cytotoxic activity of spleen cells isolated from liver graft recipients (BIO-->C3H). 30 days after transplantation 
% Specific ·'Cr release" 
Effectors" n BIO C3H BALB/C 
Naive controls 
C3H-C3H 3 3 ::: 1.2 2 :!: 1.5 3 :!: 1.9 
C3H-BIO 3 32:!: 4.5 3 :!: 1.6 10 :!: 2.0 
C3H·BALB/C 3 7 :!: 3.1 5:!: 3.5 33 :: 4.4 
After OLT 
C3H-C3H 3 2 :!: 1.2 2 :!: 1.3 2 :!: 1.3 
C3H-BIO 3 33 :t 3.1 3:t 1.7 3 :t 1.8 
C3H-BALB/C 3 3 :!: 1.4 4 :t 2.1 30 :t 3.0 
"Data expressed as mean = 1 S.D. 
bEffector cells isolated from either naive or liver transplant recipients were initially cultured for 4 days with "I -irradiated splenocytes from 
either naive syngeneic (C3H ), donor (BI0) or third party (BALB/C) animals and finally incubated with 51Cr-labelled syngeneic, donor and 
third-party target cells at an E : T ratio of 100 : 1. 
system, which for successful transplantation must be 
incorporated into the recipient's immune appara-
tus with receptor-ligand interactions of variable and 
changeable affinities. 
In this "network" viewpoint (36-40), bidirectional 
redefinition of self by the coexisting immune systems is 
not unreasonable, nor is the possibility of their eventual 
cooperation and complete mutual assimilation. The 
, 
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contention of Coutinho (37) that immunologic self-
definition is maintained by self-assertion is compatible 
with our experimental evidence in rats (7) and in our 
more complete studies of the mouse liver model. These 
studies have not shown clonally deleted recipient popu-
lations but suggest instead a state of low-grade recip-
rocal stimulation (1S). 
The iterative and metadynamic properties implicit in 
such an immune network would explain not only the 
large influence of a small number of chimeric cells but 
also the donor specificity of the consequent tolerance. If 
the detached and assimilated fragment of the donor 
immune system is able to maintain the rest of its "self" 
in its new environment, a mirror image (recipient 
specific) effect would not be surprising, such as that 
implicit in the results of both our rat and mouse 
experiments. Arnold et al. (41) have speculated that 
donor- (or recipient-) specific nonreactivity is the end 
stage of a long process that cannot be accurately assessed 
in its evolution by current in vitro techniques (42-44), 
This situation was epitomized in our mice, which were 
shown to have normal antidonor activity by mixed 
lymphocyte reaction or CML testing at a time when their 
liver allografts were beyond the danger of fatal rejection 
and already were capable of shielding other normally 
rejected donor-strain tissues and organs from immuno-
logic injury (1S)' This phenomenon has been called 
"split tolerance" (45, 46). 
We believe that multilineage donor leukocyte chi-
merism is required for these changes in the immunologic 
environment to occur. Although the presence of den-
dritic cells was emphasized in our human cases (1-6) and 
rat liver transplant experiments (7), there was also 
morphological and functional evidence that T and B 
lymphocytes and macrophages were part of the chimeric 
population. A mixture of chimeric cell lineages in 
recipient tissues was demonstrated far more conclu-
sively in the mouse experiments reported here, both 
early and late after liver transplantation. However, the 
exact quantitation of the lineage proportions at different 
time points remains to be done. 
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